Bruker Corporation (BRKR) Insider Trading Activity

NASDAQ$37.59-0.39 (-1.03%)
Market Cap
$5.78B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
323 of 875
Rank in Industry
45 of 111

BRKR Insider Trading Activity

BRKR Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$100,043
1
11
Sells
$2,909,114
8
89

Related Transactions

LAUKIEN FRANK HPRESIDENT & CEO
1
$100,043
0
$0
$100,043
Friend Cynthia Mdirector
0
$0
1
$113,990
$-113,990
ORNELL JOHN Adirector
0
$0
1
$243,087
$-243,087
PACKER RICHARD Adirector
0
$0
1
$243,230
$-243,230
Munch MarkEXEC VP&PRES BRUKER NANO INC.
0
$0
5
$2.31M
$-2.31M

About Bruker Corporation

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Insider Activity of Bruker Corporation

Over the last 12 months, insiders at Bruker Corporation have bought $100,043 and sold $2.91M worth of Bruker Corporation stock.

On average, over the past 5 years, insiders at Bruker Corporation have bought $2.08M and sold $21.5M worth of stock each year.

Highest buying activity among insiders over the last 12 months: LAUKIEN FRANK H (PRESIDENT & CEO) — $100,043.

The last purchase of 2,608 shares for transaction amount of $100,043 was made by LAUKIEN FRANK H (PRESIDENT & CEO) on 2025‑06‑06.

List of Insider Buy and Sell Transactions, Bruker Corporation

2026-03-13SaleMunch MarkEXEC VP&PRES BRUKER NANO INC.
2,000
0.0014%
$35.44
$70,880
+3.86%
2026-02-13SaleMunch MarkEXEC VP&PRES BRUKER NANO INC.
2,000
0.0013%
$36.94
$73,880
+0.86%
2026-01-15SaleMunch MarkEXEC VP&PRES BRUKER NANO INC.
2,000
0.0013%
$49.20
$98,400
-22.16%
2026-01-12SaleMunch MarkEXEC VP&PRES BRUKER NANO INC.
7,000
0.0048%
$55.00
$385,000
-27.67%
2026-01-05SaleMunch MarkEXEC VP&PRES BRUKER NANO INC.
33,843
0.0216%
$49.66
$1.68M
-22.81%
2025-12-01SalePACKER RICHARD Adirector
5,028
0.0034%
$48.38
$243,230
-11.12%
2025-11-06SaleORNELL JOHN Adirector
6,233
0.0041%
$39.00
$243,087
+8.45%
2025-09-12SaleFriend Cynthia Mdirector
3,535
0.0024%
$32.25
$113,990
+29.00%
2025-06-06PurchaseLAUKIEN FRANK HPRESIDENT & CEO
2,608
0.0017%
$38.36
$100,043
+2.27%
2025-03-10PurchaseBures ThomasChief Accounting Officer
500
0.0003%
$47.40
$23,698
-16.11%
2025-02-18PurchaseLAUKIEN FRANK HPRESIDENT & CEO
20,000
0.0134%
$50.92
$1.02M
-20.59%
2024-12-02SalePACKER RICHARD Adirector
3,350
0.0022%
$57.82
$193,683
-30.60%
2024-11-18PurchaseLAUKIEN FRANK HPRESIDENT & CEO
100,000
0.0669%
$50.14
$5.01M
-17.94%
2024-08-15SaleROSENTHAL BOBdirector
4,684
0.0032%
$63.14
$295,748
-19.36%
2024-03-04SaleRequardt Hermann Fritzdirector
15,000
0.0109%
$90.06
$1.35M
-29.10%
2024-02-28SaleBusse FalkoPRESIDENT, BIOSPIN GROUP
28,122
0.0201%
$85.48
$2.4M
-25.95%
2024-02-22SalePrause BurkhardPRES. & CEO, BRUKER BEST
15,319
0.011%
$83.30
$1.28M
-23.29%
2023-08-08SaleLAUKIEN FRANK HPRESIDENT & CEO
37,947
0.0256%
$64.81
$2.46M
+2.63%
2023-06-16SaleHerman Gerald NEXECUTIVE VICE PRESIDENT, CFO
14,242
0.0097%
$75.42
$1.07M
-5.11%
2023-05-19SaleKastner Marc Adirector
11,146
0.0075%
$75.22
$838,402
-5.05%
Total: 192
*Gray background shows transactions not older than one year

Insider Historical Profitability

26.57%
LAUKIEN FRANK HPRESIDENT & CEO
38462171
25.2677%
$1.46B9116
+26.03%
Munch MarkEXEC VP&PRES BRUKER NANO INC.
128443
0.0844%
$4.88M010
PACKER RICHARD Adirector
89174
0.0586%
$3.39M24
+5.57%
ORNELL JOHN Adirector
35212
0.0231%
$1.34M01
Friend Cynthia Mdirector
18016
0.0118%
$684,247.6808
LAUKIEN DIRK D
15862972
10.4212%
$602.48M17
LAUKIEN JOERG C
15208795
9.9914%
$577.63M47
+23.32%
LAUKIEN MARC M10 percent owner
14506348
9.5299%
$550.95M14
LAUKIEN ISOLDE10 percent owner
14160160
9.3025%
$537.8M13
Srega JuergenGroup President Bruker CALID
130936
0.086%
$4.97M01
WAGNER CHARLES F JREVP & Chief Financial Officer
99925
0.0656%
$3.8M01
KNIGHT WILLIAM JChief Financial Officer
63350
0.0416%
$2.41M30
+60.53%
KNISS RICHARDdirector
40753
0.0268%
$1.55M02
Herman Gerald NEXECUTIVE VICE PRESIDENT, CFO
36462
0.024%
$1.38M01
Busse FalkoPRESIDENT, BIOSPIN GROUP
32859
0.0216%
$1.25M01
ROSENTHAL BOBdirector
30963
0.0203%
$1.18M01
LINTON WILLIAM Adirector
29000
0.0191%
$1.1M10
+24.9%
Requardt Hermann Fritzdirector
23147
0.0152%
$879,123.0601
Prause BurkhardPRES. & CEO, BRUKER BEST
17065
0.0112%
$648,128.7004
Martin Gilles Gerard Jeandirector
14657
0.0096%
$556,672.8601
Lenggenhager RenePresident, BioSpin Group
11037
0.0073%
$419,185.2601
Kastner Marc Adirector
8051
0.0053%
$305,776.9806
VAN INGEN CHRISdirector
4577
0.003%
$173,834.4602
Bures ThomasChief Accounting Officer
3472
0.0023%
$131,866.5610
STEIN RICHARD MSecretary
3349
0.0022%
$127,195.0202
FURLONG BRENDA Jdirector
1000
0.0007%
$37,980.0001
Emmerich Wolf-Dieterdirector
0
0%
$001
Fesik Stephen W.director
0
0%
$001
*Gray background shows insiders who have made transactions during last year

BRKR Institutional Investors: Active Positions

Increased Positions202+48.33%19M+14.61%
Decreased Positions189-45.22%17M-12.71%
New Positions86New6MNew
Sold Out Positions66Sold Out4MSold Out
Total Postitions431+3.11%136M+1.9%

BRKR Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Orbis Allan Gray Ltd$680,539.009.31%14.15M+9M+202.38%2025-09-30
Fmr Llc$660,688.009.04%13.73M+5M+63.37%2025-09-30
Blackrock, Inc.$527,151.007.21%10.96M-123,759-1.12%2025-09-30
Vanguard Group Inc$500,549.006.85%10.4M-27,612-0.27%2025-09-30
Pallas Capital Advisors Llc$456,109.006.24%9.48M-20,698-0.22%2025-09-30
T. Rowe Price Investment Management, Inc.$306,924.004.2%6.38M-5M-44.19%2025-09-30
State Street Corp$179,937.002.46%3.74M-44,567-1.18%2025-09-30
Edmond De Rothschild Holding S.A.$152,351.002.08%3.17M+2M+110.32%2025-09-30
Sculptor Capital Lp$147,929.002.02%3.07M00%2025-09-30
London Co Of Virginia$144,739.001.98%3.01M-1M-25.23%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.